Opus Genetics, Inc. Revises OPGx‑BEST1 Trial Data Presentation

What Happened
Opus Genetics, Inc. announced on September 11, 2026 that it issued a revised investor data presentation (furnished as Exhibit 99.1) correcting an immaterial error in the translation of logMAR visual acuity into ETDRS letters that affected the depiction of mean best‑corrected visual acuity (BCVA) through 3 months for Cohort 1 of its ongoing Phase 1/2 trial of OPGx‑BEST1. The original presentation was used at the company’s investor conference on September 9, 2026 and previously furnished on Form 8‑K. The revised slide (Slide 15) and appendix now include corrected three‑month BCVA changes and high‑resolution microperimetry grids.

Key corrected three‑month BCVA changes by participant (treated eye / fellow eye):

• 101‑101: +12 letters / +4 letters
• 101‑104: +1 letter / −7 letters
• 102‑101: −10 letters / −8 letters
• 102‑102: +2 letters / −5 letters
• 101‑106: +6 letters / +2 letters

Key Details

• Date of revision: September 11, 2026; original presentation used on September 9, 2026.
• Correction: immaterial translation error from logMAR to ETDRS letters impacted the mean BCVA depiction on Slide 15.
• Supplemental materials: high‑resolution baseline and 3‑month microperimetry grids added to the Appendix; individual loci data shown for three participants.
• Filing: revision disclosed under Regulation FD (Item 7.01) and furnished as Exhibit 99.1 to the Form 8‑K.

Why It Matters
This filing clarifies the reported visual acuity outcomes for Cohort 1 of the early‑stage OPGx‑BEST1 trial so investors and analysts can accurately interpret the clinical data. The change is described as immaterial (a correction in data translation) and does not report new safety or financial information. Because this is Phase 1/2 data from a small cohort, investors should view the results as preliminary; the revision improves accuracy but does not by itself change the trial’s scope or status as disclosed in the company’s filings.